Karen is Co-Founder and Chairman of BioCentury Inc. and was Editor in Chief from October 1992 to August 2015.
She is a director at Ovid Therapeutics Inc., which is developing drugs for orphan diseases of the brain, and at Codiak Biosciences Inc., which is engineering exosomes to target new therapeutic spaces. Karen also serves on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She serves on the Board of Overseers of Scripps Research.
Karen holds a Ph.D. in Political Science from Stanford University and a B.A. in Politics and History from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council.
In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards.
David has devoted more than 30 years to developing information products for biotechnology executives and investors.
David is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board.
In 1996, David and BioCentury Co-Founder & Chairman Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury's ongoing contributions to the industry.
David is a graduate of the University of California at Berkeley and holds an MBA from Stanford University.
Simone serves as Vice President and Editor in Chief, bringing experience from both industry and academia in translational science, where she focused for over 15 years on the scientific, commercial and strategic considerations for advancing laboratory discoveries to products for patients.
Since joining BioCentury in 2013, Simone has written and edited on innovation from idea to patient, most recently serving as Executive Editor. Previously, she was a director of translational research at Nektar Therapeutics and a senior managing consultant at Exponent Inc., where she specialized in projects for the biopharma industry. Simone serves as an adviser on multiple university translational programs, including initiatives at the University of California and Stanford University. Simone is also active in programs to advance women's careers; she is a board member of Women In Bio and served as its President in 2013-14.
Simone is a Fulbright scholar and performed a post-doc at the University of California San Francisco. She holds a Ph.D. in Molecular Pharmacology from the Weizmann Institute of Science, and an M.A. and B.A. in Pharmacology from Cambridge University.
Adam joined BioCentury in 2018 as Vice President of Product Management & Marketing. Adam has more than 25 years of product management and business strategy experience in the business-to-business analytic and information services industry, mostly focused on health and pharmaceutical content.
Through a career spanning Informa, Elsevier, IQVIA and several small businesses, Adam has gained expertise in delivering customer value through business-to-business analytic and information services.
Adam has an MBA from Carnegie Mellon University and a B.A. in Philosophy from the University of Pennsylvania.
David is responsible for BioCentury’s technology operations, including infrastructure, enterprise computing and development of digital systems.
Prior to joining BioCentury, David worked for TechSoup Global, an international NGO providing charities with software, hardware, services and training; IdeaBlade, a start-up delivering development solutions; and Molson Breweries, where he was Director of Information Technology on the Western Canada Executive Team.
In 2003, David was part of the first graduating class of the Stanford Information Technology Executive program; he is also a graduate of the Harvard Executive Program on mobile finance.
David is a proponent of empowering girls of color in STEM and has volunteered with Black Girls Code. From there, he has taken learnings to promote mobile-first design in software, social media integration and strong design thinking processes in his leadership role.
David holds a B.A. in Economics and Business from the University of Calgary and took graduate studies in Economics at the University of Alberta.
Bennet, who joined BioCentury in 2004, has had an extensive career as a senior financial executive for development stage biotechnology and technology companies, having taken two companies public, and having completed numerous equity and debt financings and M&A transactions. He was CFO at InterMune Inc., Valentis Inc. and Technology Modeling Associates Inc., and held senior financial positions at Metra Biosystems Inc. and Advanced Polymer Systems Inc.
Bennet received his B.A. in Mathematical Economics from Pomona College and earned his MBA from Harvard University.
Eric leads BioCentury’s Sales and Customer Engagement teams. He also manages BioCentury’s investor conferences BioEquity Europe, NewsMakers in the Biotech Industry and Future Leaders in the Biotech Industry. BioCentury Conferences
Eric has dedicated his career at BioCentury to building networks among C-level executives and investment decision-makers.
Eric joined BioCentury in 1993 as its first Staff Writer. He became BioCentury’s chief financial writer in 1996 when he originated "Ebb & Flow," BioCentury's capital markets column. As Senior Editor for News, Eric managed BioCentury's news operations until 2004, when he joined the management team as Associate Publisher. In 2007 he was named Publisher.
Prior to joining BioCentury, Eric was in equity sales for Merrill Lynch.
Eric holds an A.B. in Communication from Stanford University.
Josh leads BioCentury’s Business Development team and is responsible for building BioCentury’s corporate relationships with biopharma executives, investors and key industry stakeholders.
He has dedicated much of his career to building cross-border relationships between Asia, in particular China, and the West.
In this capacity, Josh created and manages BioCentury’s China Healthcare Summit conference for Chinese and Western biopharma executives and investors, in collaboration with BayHelix. BioCentury Conferences
Prior to joining BioCentury in 2014, Josh created and led the emerging markets group for Elsevier Business Intelligence.
He is a member of BayHelix, the professional organization for China life sciences executives, and serves on the editorial board of the World Korea Medical Journal.
Josh graduated from the University of Virginia with a B.A. in Economics and International Relations.
Susan joined BioCentury in 2006, bringing with her extensive experience in the legal profession in New York. She holds a B.A. in Political Science from Fairfield University and a J.D. from Fordham University School of Law.